Skip to Main Content
Skip Nav Destination

Chemo, PARPi, Endocrine Therapy: Addressing Resistance with New Weapons

June 7, 2024

Abstract: Resistance to taxane chemotherapy, PARP inhibition, and endocrine-agent in ER-positive breast cancer, remains problematic, but new approaches are emerging. Dendrimer nanoparticles may allow more effective delivery of cabazitaxel, and two first-in-class candidate drugs targeting USP1 and KAT6A/B, respectively, appear safe, tolerable, and show encouraging activity. 

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal